FDA Granted Fast Track Status to Cesalatamig
The drug is being developed as a potential treatment for patients with advanced non-small cell lung cancer.
Updated on Sept. 20, 2026 in Cancer
Live Poll
Should the FDA grant faster approval processes for promising new experimental cancer treatments?
The FDA has granted Fast Track Designation to the PD-1/VEGF bispecific antibody cesalatamig, also known as AI-081. This designation is intended to expedite the development of the drug for patients with non-small cell lung cancer whose disease progressed after prior immunotherapy and chemotherapy.
Why it matters
This regulatory step supports the rapid advancement of a new therapeutic option for patients with resistant lung cancer. It aims to accelerate the clinical path for a drug that is currently undergoing trials in the United States and China.
Cesalatamig exhibits a 40-fold higher affinity for VEGF than existing bevacizumab-based bispecific inhibitors. The global BiPAVE-001 trials are currently active at more than 50 clinical sites across the United States and China.
The players
OncoC4
Headquartered in Rockville, Maryland, this biopharmaceutical company specializes in the development of novel immunotherapies.
FDA
The United States Food and Drug Administration is the federal agency responsible for regulating pharmaceuticals and medical devices.
The details
OncoC4 is currently evaluating cesalatamig in Phase 1 and 2 studies, which utilize dose escalation, expansion, and optimization designs to measure safety and clinical activity. The company is now preparing to move the drug into registrational Phase 3 development for patients with PD-(L)1-refractory or resistant non-small cell lung cancer.
Timeline
September 16, 2026: The FDA granted Fast Track Designation to cesalatamig.
Health Landscape
The granting of this status follows the standard procedures set by the FDA Fast Track Designation program to facilitate earlier access to promising oncology medications. This development reflects the ongoing shift toward bispecific antibodies that target multiple biological pathways to overcome drug resistance in cancer therapy.
While the drug is still in clinical trials, this designation could eventually expand the treatment options available to patients with advanced, treatment-resistant lung cancer. Patients should consult with their oncologists to determine if they meet the criteria for enrollment in ongoing clinical studies.
The takeaway
The progression of cesalatamig into later-stage development highlights the potential of dual-targeting therapies to improve outcomes in resistant cancer cases. Patients and families affected by lung cancer can monitor clinical trial registries for updates on future patient recruitment phases.
Further reading
Learn more about the latest progress in oncology by visiting our Cancer section.
Source note: This article includes information reported by Drugs.
Live Poll
Should the FDA grant faster approval processes for promising new experimental cancer treatments?
